Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863102 | 0.82 | ATR (0.36) | ATRCYP17A1CA1CA2CA12 | |
| SCHEMBL25829865 | 0.81 | ATR (0.41) | ATRCYP17A1CA1CA2CA12 | |
| SCHEMBL25303704 | 0.80 | — | — | |
| SCHEMBL25863127 | 0.79 | GAA (0.30) | — | |
| SCHEMBL25263534 | 0.79 | GAA (0.30) | — | |
| SCHEMBL25830529 | 0.77 | ATR (0.34) | ATRCA1CA2 | |
| SCHEMBL25829322 | 0.75 | ATR (0.39) | ATRCYP17A1CA1CA2CA12 | |
| SCHEMBL31290291 | 0.74 | CTSS (0.42) | ATRCYP17A1CA1CA2 | |
| SCHEMBL20865565 | 0.71 | ATR (0.40) | ATRCYP17A1CA1CA2 | |
| SCHEMBL25829763 | 0.69 | CYP17A1 (0.42) | ATRCYP17A1CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023137007-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137007-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ACE2, HTR3C, SARS1 | ATR 2583/4885CYP17A1 476/4885CA1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.